Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of emixustat versus placebo for macular atrophy in Stargardt disease
2018-003498-82Phase 3Unknown
- Sponsor
- Kubota Vision
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fundus Flavimaculatus (FF) comparing Emixustat hydrochloride with Placebo (2 arms). Primary endpoint: Mean rate of change in total area of macular atrophy lesions. Status: unknown.
02
Drugs
emixustat
03
Conditions
Fundus Flavimaculatus (FF)
Beyond the preview
Go deeper on 2018-003498-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003498-82.